PPARG and type 2 diabetes mellitus: To date, most studies have evaluated the role of PPARγ in major metabolic organs such as liver, adipocytes, pancreas, or skeletal muscles (Tontonoz and Spiegelman, 2008; Ahmadian et al., 2013), leading to target PPARγ for the treatment of type 2 diabetes with the development of the thiazolidinedione (TZD) class of drugs (Lehmann et al., 1995).